ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Kakala
|
943 |
411K |
0 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
943
|
411K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Kakala
|
943 |
411K |
2 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
943
|
411K
|
2
|
|
ASX - By Stock
|
M4M |
Price Analysis
|
|
Kakala
|
2 |
1.4K |
2 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
2
|
1.4K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Institutional Placement and Entitlement Offer
|
|
Kakala
|
513 |
135K |
0 |
07/01/24 |
07/01/24 |
ASX - By Stock
|
513
|
135K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Institutional Placement and Entitlement Offer
|
|
Kakala
|
513 |
135K |
8 |
07/01/24 |
07/01/24 |
ASX - By Stock
|
513
|
135K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE
|
|
Kakala
|
299 |
106K |
5 |
26/07/22 |
26/07/22 |
ASX - By Stock
|
299
|
106K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Sold out a year ago
|
|
Kakala
|
39 |
10K |
12 |
14/12/21 |
14/12/21 |
ASX - By Stock
|
39
|
10K
|
12
|
|
ASX - By Stock
|
MSB |
Sold out a year ago
|
|
Kakala
|
39 |
10K |
44 |
14/12/21 |
14/12/21 |
ASX - By Stock
|
39
|
10K
|
44
|
|
ASX - By Stock
|
BRN |
Market Cap
|
|
Kakala
|
13 |
6.7K |
3 |
20/01/21 |
20/01/21 |
ASX - By Stock
|
13
|
6.7K
|
3
|
|
ASX - By Stock
|
BRN |
Re:
high level views
|
|
Kakala
|
7 |
2.6K |
3 |
20/01/21 |
20/01/21 |
ASX - By Stock
|
7
|
2.6K
|
3
|
|
ASX - By Stock
|
BRN |
high level views
|
|
Kakala
|
7 |
2.6K |
1 |
14/01/21 |
14/01/21 |
ASX - By Stock
|
7
|
2.6K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse
|
|
Kakala
|
311 |
93K |
1 |
09/01/21 |
09/01/21 |
ASX - By Stock
|
311
|
93K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Kakala
|
1.0K |
521K |
7 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
521K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Kakala
|
796 |
398K |
4 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
398K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Kakala
|
796 |
398K |
0 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
398K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Kakala
|
796 |
398K |
0 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
398K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Kakala
|
796 |
398K |
0 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
398K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Kakala
|
796 |
398K |
1 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
398K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Kakala
|
796 |
398K |
0 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
398K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
Kakala
|
1.0K |
423K |
11 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
423K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Guess the opening price - if ARDS halted due supreme efficacy
|
|
Kakala
|
416 |
133K |
5 |
14/12/20 |
14/12/20 |
ASX - By Stock
|
416
|
133K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Guess the opening price - if ARDS halted due supreme efficacy
|
|
Kakala
|
416 |
133K |
0 |
14/12/20 |
14/12/20 |
ASX - By Stock
|
416
|
133K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Guess the opening price - if ARDS halted due supreme efficacy
|
|
Kakala
|
416 |
133K |
9 |
14/12/20 |
14/12/20 |
ASX - By Stock
|
416
|
133K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Guess the opening price - if ARDS halted due supreme efficacy
|
|
Kakala
|
416 |
133K |
3 |
14/12/20 |
14/12/20 |
ASX - By Stock
|
416
|
133K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
Kakala
|
572 |
255K |
6 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
255K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
Kakala
|
811 |
339K |
6 |
27/11/20 |
27/11/20 |
ASX - By Stock
|
811
|
339K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
AGM Discussion
|
|
Kakala
|
254 |
100K |
1 |
25/11/20 |
25/11/20 |
ASX - By Stock
|
254
|
100K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
Kakala
|
811 |
339K |
2 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
811
|
339K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
Kakala
|
811 |
339K |
4 |
22/11/20 |
22/11/20 |
ASX - By Stock
|
811
|
339K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
More analysis less fighting
|
|
Kakala
|
7 |
3.3K |
3 |
16/11/20 |
16/11/20 |
ASX - By Stock
|
7
|
3.3K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
More analysis less fighting
|
|
Kakala
|
7 |
3.3K |
4 |
16/11/20 |
16/11/20 |
ASX - By Stock
|
7
|
3.3K
|
4
|
|
ASX - By Stock
|
MSB |
More analysis less fighting
|
|
Kakala
|
7 |
3.3K |
21 |
16/11/20 |
16/11/20 |
ASX - By Stock
|
7
|
3.3K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Kakala
|
13K |
5.0M |
2 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Today's Price 29-09-2020
|
|
Kakala
|
10 |
4.6K |
2 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
10
|
4.6K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Kakala
|
13K |
5.0M |
4 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Kakala
|
13K |
5.0M |
3 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Kakala
|
13K |
5.0M |
4 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Kakala
|
13K |
5.0M |
9 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Covid 19
|
|
Kakala
|
4 |
1.8K |
1 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
4
|
1.8K
|
1
|
|
ASX - By Stock
|
MSB |
Covid 19
|
|
Kakala
|
4 |
1.8K |
31 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
4
|
1.8K
|
31
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Kakala
|
13K |
5.0M |
4 |
25/09/20 |
25/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
4
|
|
ASX - By Stock
|
MSB |
This Friday!!!
|
|
Kakala
|
30 |
15K |
5 |
23/09/20 |
23/09/20 |
ASX - By Stock
|
30
|
15K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Kakala
|
13K |
5.0M |
0 |
22/09/20 |
22/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Kakala
|
18K |
7.0M |
38 |
13/09/20 |
13/09/20 |
ASX - By Stock
|
18K
|
7.0M
|
38
|
|
ASX - By Stock
|
MSB |
Re:
Naysayers
|
|
Kakala
|
10 |
2.2K |
5 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
10
|
2.2K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Naysayers
|
|
Kakala
|
10 |
2.2K |
0 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
10
|
2.2K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
Kakala
|
2.0K |
700K |
5 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
700K
|
5
|
|
ASX - By Stock
|
MSB |
Naysayers
|
|
Kakala
|
10 |
2.2K |
16 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
10
|
2.2K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
What a ridiculous Response
|
|
Kakala
|
2 |
995 |
2 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
2
|
995
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Kakala
|
23K |
13M |
13 |
29/05/20 |
29/05/20 |
ASX - By Stock
|
23K
|
13M
|
13
|
|